Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterNo recent work listed

Xiaomeng Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3794-6823; OpenAlex author ID A5100327761. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper

Papers 2

  1. RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer. Co-author DOI 10.1186/s12935-019-1077-6↗
  2. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0113586↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhigang Ren · 1 shared paper, 2019 · strength 0.12
  2. Robert J. Gillies · 1 shared paper, 2014 · strength 0.04
  3. Pawel Swietach · 1 shared paper, 2014 · strength 0.04
  4. Kate M. Bailey · 1 shared paper, 2014 · strength 0.04
  5. Amanda F. Baker · 1 shared paper, 2014 · strength 0.04
  6. Charles P. Hart · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.